SEC Form 4 · accession 0001209191-16-127377
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nassim Usman
Officer — President and CEO · Director
Period of report
Jun 9, 2016
Accepted (ET)
Jun 13, 2016 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.88 | Jun 9, 2016 | A | 7,500 | A | — | Jun 9, 2026 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Award vests monthly over one (1) year from the date of grant.